AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00187135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L.M.X4
Description: All patients will have EMLA or LMX4 cream applied at the anticipated site of the bone marrow aspiration to ensure topical anesthesia, and will receive a total intravenous anesthetic technique (TIVA). In order to optimize transdermal anesthesia LMX4 application has to be over at least 30 minutes.
Study NCT00187135 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: L.M.X4
Description: All patients will have EMLA or LMX4 cream applied at the anticipated site of the bone marrow aspiration to ensure topical anesthesia, and will receive a total intravenous anesthetic technique (TIVA). In order to optimize transdermal anesthesia LMX4 application has to be over at least 30 minutes.
Study NCT00187135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol - 1 mg/kg increments every 30 seconds-1minute until loss of consciousness is indicated by lack of response to verbal command and loss of eyelid reflex.
Study NCT03891056 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: metabolic surgery
Description: The study will randomize patients into two arms, one where a laparoscopic gastric bypass will be performed and another that will perform slevee gastrectomy.
Study NCT03706378 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wheat Yellow Noodle
Description: Wheat Yellow Noodle will contain 50g of available carbohydrate
Study NCT03706378 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beta-glucan yellow Noodle
Description: Beta-glucan yellow noodle will contain 50g of available carbohydrate
Study NCT03706378 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rice Roll
Description: Rice Roll will contain 50g of available carbohydrate
Study NCT03706378 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rice Roll with resistant starch
Description: Rice Roll fortified with resistant starch will contain 50g of available carbohydrate
Study NCT03706378 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose Jelly
Description: Jelly and bread will contain 50g of available carbohydrate. The jelly will contain 25g of sucrose
Study NCT03706378 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isomaltulose Jelly
Description: Jelly and bread will contain 50g of available carbohydrate. The jelly will contain 25g of Isomaltulose
Study NCT00919373 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Substrate modification
Description: Catheter Ablation procedure - Substrate modification in sinus rhythm in case of unstable induced monomorphic Ventricular Tachycardia (VT) which does not allow mapping and ablation in tachycardia, or noninducible stable clinical VT.
Study NCT00919373 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VT ablation
Description: Catheter Ablation of Ventricular Tachycardia (VT) in case of stable VT
Study NCT00919373 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ICD Implantation
Description: Implantation of a marked released Implantable Cardioverter Defibrillator manufactured by St. Jude Medical
Study NCT00729859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyline
Description: Acyline 300 μg/kg injections every two weeks (2 doses) for 28 days + placebo Testosterone gel daily for 28 days + placebo oral anastrozole pill daily for 28 days
Study NCT00729859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyline + Testosterone gel
Description: Acyline 300 μg/kg injections every two weeks (2 doses) for 28 days + Testosterone gel 100 mg daily for 28 days + placebo oral pill 1 mg daily for 28 days
Study NCT00729859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyline + testosterone gel + anastrozole
Description: Acyline 300 μg/kg injections every two weeks (2 doses) for 28 days + Testosterone gel 100 mg daily for 28 days + oral anastrozole pill 1 mg daily for 28 days
Study NCT03486977 — intervention group
Intervention type: PROCEDURE
Intervention: Evaluation of disease and follow-up
Description: Correspondence medical consultation with specific device
Study NCT00436358 — intervention group
Intervention type: OTHER
Intervention: Not applicable: none
Description: Please refer to the detailed description section
Study NCT01161641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODSH at 0.125 mg/kg/h
Description: ODSH 1000 mg vials containing 20 cc of normal saline (50 mg/ml) to be prepared for 96-h IV infusion with normal saline based on subject's weight and dose assigned by Study Cohort 1 of 0.125 mg/kg/h.
Study NCT01161641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODSH at 0.375 mg/kg/h
Description: ODSH 1000 mg vials containing 20 cc of normal saline (50 mg/ml) to be prepared for 96-h IV infusion with normal saline based on subject's weight and dose assigned by Study Cohort 3 of 0.375 mg/kg/h.
Study NCT01161641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODSH at 0.250 mg/kg/h
Description: ODSH 1000 mg vials containing 20 cc of normal saline (50 mg/ml) to be prepared for 96-h IV infusion with normal saline based on subject's weight and dose assigned by Study Cohort 2 of 0.250 mg/kg/h.
Study NCT03749655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Promotion
Description: The physical activity (PA) promotion intervention will be provided only to the intervention group, and will include: 1) a step-counter with a digital display, 2) an interview discussing motivational issues, favourite daily activities and strategies to become more physically active; and 3) a tailored physical activity coaching plan including an Individualised activity goal (in steps/day) revised twice weekly through consultation sessions (16 sessions in total). Patients' targets will be revised twice weekly during the consultation sessions which will be incorporated into the Pulmonary rehabilitation sessions. The aim is to increase physical activity by 10% each week. The goal can be altered if required.
Study NCT00246974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: intravenous
Study NCT00214786 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Islet cell transplantation
Description: Allogenic islet transplantation
Study NCT02953444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thirty-Second Mindfulness Practice
Study NCT02953444 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Three-Minute Mindfulness Practice
Study NCT02942368 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Transcranial direct current stimulation with placement of the anode over the F3 region of the scalp and the cathode over the right supraorbital region.
Study NCT02737969 — intervention group
Intervention type: DEVICE
Intervention: Transesophageal Echocardiography/angiography (TEE/Angio)
Description: The TEE probe will be inserted into the patient's esophagus, after anesthetic induction or conscious sedation is administered, and removed after the completion of the procedure. Once the TEE probe is placed, the interventional cardiologist will acquire 2 fluoroscopic images with the TEE probe. These images will be used to co-register the ultrasound and fluoroscopy systems. As part of routine care, TEE and fluoroscopy images will be acquired throughout the procedure for clinical purposes. As new fluoroscopy images are acquired, the prototype software will automatically track the location of the TEE probe. When the echocardiographer has an image of a cardiac structure of interest, he may use the prototype software to place landmarks.~The echocardiographer may then press a button to have the landmarks displayed on the fluoroscopy image that is only visible on an assist monitor and will not interfere with the standard fluoroscopy imaging monitor.
Study NCT01938651 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: diffusion-weighted magnetic resonance imaging
Description: Undergo DW-MRI
Study NCT01938651 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dynamic contrast-enhanced magnetic resonance imaging
Description: Undergo DCE-MRI
Study NCT01494844 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Respiratory monitor patient interface.
Description: Wear each interface for 20 minutes
Study NCT03205228 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: A capsule of Omeprazole 20 mg \& 1 capsule of placebo will be given in individual subject, once daily for 4 weeks. Both drugs will be presented in the same appearance (white capsule).
Study NCT03205228 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: psychoeducation
Description: Psychoeducation will be given by psychologists at the Day 1 and Day 15 of the study period.One white capsule of placebo will be given once daily for 4 weeks of the study period.
Study NCT03205228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flupentixol +Melitracen
Description: A capsule containing of a tablet of melitracen 10 mg + flupentixol 0.5 mg \& a capsule of placebo will be given once daily, for 4 weeks. Both would be presented in the same appearance (white capsule)
Study NCT00179777 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrolysed infant formula
Description: Participants in the Hydrolysed infant formula -group received the test formula, casein hydrolysate (Nutramigen™, Mead Johnson Nutritionals), not containing antigenic CM protein, whenever breast milk is not available.
Study NCT00179777 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nonhydrolysed infant formula
Description: Participants in the Nonydrolysed infant formula -group received the CM protein containing control formula which has an addition (20 %) of Nutramigen, whenever breast milk is not available.
Study NCT03567395 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Melatonin (5 mg sublingual tablet) administered for 3 days
Study NCT03567395 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Honey
Description: Raw Honey (1.5 tablespoons) administered for 3 days
Study NCT04673474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay022
Description: Participants will receive a single oral dose of Hemay022 tablet in fasted condition on Day 1 of treatment period 1 followed by a single oral dose of Hemay022 tablet in fed condition on Day 8 of treatment period 2. A washout period of 7 days will be maintained between the 2 treatment periods.
Study NCT04673474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay022
Description: Participants will receive a single oral dose of Hemay022 tablet in fed condition on Day 1 of treatment period 1 followed by a single oral dose of Hemay022 tablet in fasted condition on Day 8 of treatment period 2. A washout period of 7 days will be maintained between the 2 treatment periods.
Study NCT02414360 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shortened Format
Description: Shortened format of a systematic review
Study NCT02414360 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Full Length
Description: Full length systematic review
Study NCT00246974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: intravenous
Study NCT00246974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: intravenous
Study NCT00846001 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary artery bypass grafting
Description: Standard coronary surgry according guidelines
Study NCT00846001 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting
Description: Standard coronary surgry according guidelines
Study NCT00187135 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: Propofol - 1 mg/kg increments every 30 seconds-1minute until loss of consciousness is indicated by lack of response to verbal command and loss of eyelid reflex.
Study NCT01682213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Following definitive surgical resection, eligible patients will receive dabrafenib at 150 mg twice a day by mouth for 4 cycles (± 5 days). One cycle is 28 days.
Study NCT00846001 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epicardial implantation of cardiac resynchronization therapy device
Description: During the cardiac surgery, the CABG+CRT arm patients will be implanted with epicardial leads to the right atrium, right and left ventricles. Left ventricle leads will be fixed to the posterolateral wall provided that there is no scar or fat tissue (behind and 2-3 cm apical than obtuse marginal artery). Right atrial and right ventricular leads will be fixed in a traditional way. Then the leads will be guided into a preformed pocket (left subclavian region) and connected with the CRT device.
Study NCT01736397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Citrate
Description: Dose depends on serum phosphorus levels collected at each study visit.
Study NCT01736397 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04061512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone, cyclophosphamide, rituximab
Description: DRC Arm (chemotherapy) consists of dexamethasone, cyclophosphamide and rituximab treatment
Study NCT04061512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab, ibrutinib
Description: RI Arm (chemotherapy free) consists of rituximab and ibrutinib treatment
Study NCT00246974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: intravenous
Study NCT00246974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: oral
Study NCT02353065 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound imaging
Description: Point of care ultrasound of fracture site during and post-reduction
Study NCT02353065 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Bedside x-ray
Description: Portable x-ray of fracture post-reduction
Study NCT04352413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLM60
Description: Administration: Intravenous infusion
Study NCT01025856 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rich in MUFA diet -PA
Description: The patients will follow a rich in MUFA diet without a physical activity program.
Study NCT01025856 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high fiber/low glycemic index diet + pa
Description: patients will follow for two months a high fibre/ low glycemic index diet with a physical activity program.
Study NCT01025856 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rich in MUFA diet+PA
Description: Patients will follow for two months a rich in MUFA diet with a physical activity program.
Study NCT01025856 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High fibre/low glycemic index diet-PA
Description: Patients will follow for two months a high fibre/low glycemic index diet without a physical activity program.
Study NCT01142037 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cooked parsnips with parsley
Description: Beginning on Day 9 participants will be given cooked parsnips with parsley at a dose of 2 grams total apiaceous vegetable/kilogram body weight for period 1, and 4 gram/kilogram body weight for period 2.
Study NCT02240758 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: confocal endomicroscopy with the CELLVIZIO® system (Mauna Kea technology)
Description: The CELLVIZIO® system (Mauna Kea technology) will be used for confocal endomicroscopy during a surgical procedure (either open surgical approach or stereotaxic biopsy). The probe dedicated to the CELLVIZIO® system will be positioned against the surface of the brain, sequences will be acquired, and finally compared with anatomapathology exams. Two specific medications will be used as contrast agent in the study: Fluorescein FAURE 500mg/5mL IV with a maximum of two doses per patient OR 5 amino-levulinic hydrochloride (GLIOLAN, MEDAC) orally at the dose of 20mg/kg of body weight.
Study NCT00957268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets
Study NCT03820154 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Skin Prick Test
Description: Skin Prick Testing with inhalant allergens
Study NCT03820154 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Skin Prick Test TAPE
Description: Skin Prick Testing with a Tape, integrating the allergens and needles
Study NCT03364374 — intervention group
Intervention type: BEHAVIORAL
Intervention: Postural counseling
Description: A therapist will provide verbal/physical cues to improve the participants posture
Study NCT03635047 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AL002
Description: Single-doses of AL002 in up to 9 dose-escalating cohorts
Study NCT02965820 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Opti-Free® PureMoist® contact lens solution
Study NCT02965820 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Habitual Multi-Purpose Contact Lens Solution
Study NCT03635047 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Saline solution will be administered as a single infusion for each cohort in a ratio of 6 active and 2 placebo subjects for HV and 10 active and 2 placebo for patients
Study NCT02965820 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Habitual Contact Lenses
Description: Subject's habitual contact lens brand worn in a daily wear modality for 30 days.
Study NCT02806349 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: American Ginseng
Description: herb
Study NCT02806349 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Konjac-glucomannan fiber blend
Description: Blend of 2 viscous fibers: konjac mannan and xanthan
Study NCT02806349 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Fiber matched control for intervention (corn starch and wheat bran)
Study NCT03729544 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: On-screen computerized decision support alert
Description: On-screen electronic alert during the outpatient clinical encounter that notifies him or her that the patient should be screened for CTEPH
Study NCT00607737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: 3 cutaneous injections
Study NCT00607737 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: 3 cutaneous injections
Study NCT03361436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Given IV
Study NCT03361436 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study NCT03198351 — intervention group
Intervention type: DRUG
Intervention: Teriflunomide (HMR1726)
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT04557332 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: On the Dot Mobile app
Description: On the Dot is a mobile app to support HIV medication adherence. The mobile app is linked to a clinician portal through which participants can receive adherence support.
Study NCT00082446 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live vaccinia virus vaccine
Description: Dryvax®: 0.25 mL of vaccine will be administered by the standard route of scarification using a bifurcated needle on day 112 for Groups A, B, C, D and F.
Study NCT00082446 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Live vaccinia virus vaccine
Description: Dryvax®: 0.25 mL of vaccine will be administered by the standard route of scarification using a bifurcated needle on day 112 for Groups A, B, C, D and F.
Study NCT00082446 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA Smallpox Vaccine
Description: Imvamune/MVA-BN 1x10\^8 will be administered intramuscularly to Group F on day 0 and day 28.
Study NCT00082446 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA Smallpox Vaccine
Description: Imvamune/MVA-BN Groups A, B C and E will be administered subcutaneously: 2x10\^7, 5x10\^7, 1x10\^8, 1x10\^8, respectively, on days 0 and day 28.
Study NCT00082446 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Group E will receive sterile saline placebo for injection via scarification on day 112.
Study NCT00082446 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Group D will receive sterile saline placebo for injection subcutaneously on day 0 and day 28.
Study NCT00513461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-adenosyl-L-methionine disulfate p-toluene-sulfonate
Description: Given PO
Study NCT01895270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isradipine
Description: Isradipine extended release formulation
Study NCT01895270 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will consist of microcrystalline cellulose.
Study NCT00513461 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study NCT02638831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine
Description: Ketorolac tromethamine gel 2% for external application. Column of gel about 3-5 cm is applied on the area of maximum pain three times a day for 10 days